Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCAX NASDAQ:BDTX NASDAQ:MGTX NASDAQ:VALN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCAXBicara Therapeutics$12.00+0.8%$10.81$7.80▼$28.09$651.48MN/A266,722 shs289,451 shsBDTXBlack Diamond Therapeutics$2.88+2.9%$2.76$1.20▼$6.33$159.42M2.93826,905 shs678,683 shsMGTXMeiraGTx$7.33+0.4%$7.85$3.86▼$8.98$587.27M1.29301,005 shs249,378 shsVALNValneva$8.77+1.6%$7.91$3.62▼$12.25$753.08M1.79150,390 shs130,301 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCAXBicara Therapeutics+0.84%-0.17%+7.91%+8.79%+1,199,999,900.00%BDTXBlack Diamond Therapeutics+2.86%+0.35%+1.77%+15.66%-50.09%MGTXMeiraGTx+0.41%-1.48%-6.51%+33.76%+87.47%VALNValneva+1.62%+0.23%+16.93%+38.11%+20.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCAXBicara TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABDTXBlack Diamond Therapeutics3.3018 of 5 stars3.61.00.00.03.61.71.9MGTXMeiraGTx4.4858 of 5 stars3.53.00.04.83.22.50.6VALNValneva1.9838 of 5 stars3.53.00.00.01.80.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCAXBicara Therapeutics 3.00Buy$32.25168.76% UpsideBDTXBlack Diamond Therapeutics 3.17Buy$12.40330.56% UpsideMGTXMeiraGTx 3.00Buy$24.00227.42% UpsideVALNValneva 3.00Buy$15.3374.84% UpsideCurrent Analyst Ratings BreakdownLatest BDTX, MGTX, VALN, and BCAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025VALNValnevaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$14.008/25/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.008/22/2025BCAXBicara TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$41.00 ➝ $40.008/19/2025VALNValnevaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.008/18/2025BCAXBicara TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$36.008/15/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.008/12/2025BCAXBicara TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$30.008/11/2025BDTXBlack Diamond TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/11/2025BDTXBlack Diamond TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.007/1/2025BDTXBlack Diamond TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform$11.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCAXBicara TherapeuticsN/AN/AN/AN/A$7.98 per shareN/ABDTXBlack Diamond Therapeutics$70M2.34N/AN/A$2.33 per share1.24MGTXMeiraGTx$33.28M17.72N/AN/A$0.04 per share183.25VALNValneva$183.52M4.07$0.10 per share90.57$2.49 per share3.52Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCAXBicara Therapeutics-$68M-$3.17N/AN/AN/AN/A-21.67%-20.89%11/11/2025 (Estimated)BDTXBlack Diamond Therapeutics-$69.68M$0.2312.52N/AN/AN/A12.70%9.58%11/4/2025 (Estimated)MGTXMeiraGTx-$147.79M-$2.04N/A19.29N/A-415.39%-314.44%-63.28%11/12/2025 (Estimated)VALNValneva-$13.25M-$0.98N/AN/AN/A-33.87%-34.78%-13.43%11/6/2025 (Estimated)Latest BDTX, MGTX, VALN, and BCAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MGTXMeiraGTx-$0.52-$0.48+$0.04-$0.48$8.00 million$3.69 million8/12/2025Q2 2025BCAXBicara Therapeutics-$0.54-$0.50+$0.04-$0.50N/AN/A8/12/2025Q2 2025VALNValneva-$0.27-$0.16+$0.11-$0.16$46.28 million$54.84 million8/7/2025Q2 2025BDTXBlack Diamond Therapeutics-$0.25-$0.19+$0.06-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCAXBicara TherapeuticsN/AN/AN/AN/AN/ABDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AVALNValnevaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCAXBicara TherapeuticsN/A25.8025.80BDTXBlack Diamond TherapeuticsN/A8.738.73MGTXMeiraGTx26.290.880.88VALNValneva0.662.271.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCAXBicara TherapeuticsN/ABDTXBlack Diamond Therapeutics95.47%MGTXMeiraGTx67.48%VALNValneva11.39%Insider OwnershipCompanyInsider OwnershipBCAXBicara TherapeuticsN/ABDTXBlack Diamond Therapeutics5.97%MGTXMeiraGTx7.50%VALNValneva14.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCAXBicara Therapeutics3254.56 millionN/AN/ABDTXBlack Diamond Therapeutics9056.94 million53.54 millionOptionableMGTXMeiraGTx30080.45 million74.41 millionOptionableVALNValneva70085.09 million72.41 millionNot OptionableBDTX, MGTX, VALN, and BCAX HeadlinesRecent News About These CompaniesValneva Reports Positive Phase 2 Results for Lyme Disease VaccineSeptember 3 at 12:54 PM | msn.comPfizer, Valneva boosted by updated vaccine data ahead of moment in the Lyme-lightSeptember 3 at 12:54 PM | fiercebiotech.comFValneva Shares Rise on Lyme Disease Vaccine Study DataSeptember 3 at 7:54 AM | marketwatch.comValneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine CandidateSeptember 3 at 2:00 AM | globenewswire.comChikungunya: Ixciq, the first authorized vaccine against the virus, under scrutinySeptember 2 at 11:20 PM | lemonde.frLFDA License Suspension Ends Use of Chikungunya Vaccine Ixchiq in USAugust 29, 2025 | infectiousdiseaseadvisor.comIHC Wainwright Reiterates "Buy" Rating for Valneva (NASDAQ:VALN)August 27, 2025 | marketbeat.comValneva (NASDAQ:VALN) Shares Gap Down - Time to Sell?August 27, 2025 | marketbeat.comFDA Suspends Valneva Vaccine’s License Following New Reports of Adverse EventsAugust 27, 2025 | medcitynews.comMValneva has biologics license withdrawn for chikungunya vaccineAugust 27, 2025 | thepharmaletter.comTAs Chikungunya Spreads Worldwide, FDA Halts Use of Only U.S.-Approved VaccineAugust 26, 2025 | managedhealthcareexecutive.comMValneva Outlook: Safety Blow To Ixchiq And Valuation ConcernsAugust 26, 2025 | seekingalpha.comValneva Stock Tumbles 19% After FDA Suspension Of Ixchiq License In US, Wall Street Divided On The ImpactAugust 26, 2025 | msn.comFDA: Valneva’s Ixchiq unpicked for safety in chikungunyaAugust 25, 2025 | bioworld.comBUS suspends chikungunya vaccine Ixchiq over 'serious' side effects: ValnevaAugust 25, 2025 | e.vnexpress.netEFDA Suspends U.S. License of Chikungunya VaccineAugust 25, 2025 | purdueexponent.orgPValneva stock tumbles as FDA suspends license for IXCHIQ vaccineAugust 25, 2025 | za.investing.comValneva Shares Tumble After Chikungunya Vaccine License Suspended in U.S.August 25, 2025 | marketwatch.comSafety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In USAugust 25, 2025 | benzinga.comFDA does a 180, suspending use of Valneva's chikungunya vaccineAugust 25, 2025 | fiercepharma.comFFDA suspends license for Valneva’s chikungunya shotAugust 25, 2025 | biopharmadive.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDTX, MGTX, VALN, and BCAX Company DescriptionsBicara Therapeutics NASDAQ:BCAX$12.00 +0.10 (+0.84%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$11.70 -0.30 (-2.46%) As of 09/3/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Black Diamond Therapeutics NASDAQ:BDTX$2.88 +0.08 (+2.86%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$2.92 +0.04 (+1.22%) As of 09/3/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.MeiraGTx NASDAQ:MGTX$7.33 +0.03 (+0.41%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$7.34 +0.00 (+0.07%) As of 09/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Valneva NASDAQ:VALN$8.77 +0.14 (+1.62%) As of 09/3/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
